Fluvoxamine (BioDeep_00000001988)

 

Secondary id: BioDeep_00000405825

human metabolite blood metabolite


代谢物信息卡片


(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine

化学式: C15H21F3N2O2 (318.1555)
中文名称: 氟伏沙明
谱图信息: 最多检出来源 Homo sapiens(blood) 59.52%

Reviewed

Last reviewed on 2024-09-14.

Cite this Page

Fluvoxamine. BioDeep Database v3. PANOMIX ltd, a top metabolomics service provider from China. https://query.biodeep.cn/s/fluvoxamine (retrieved 2024-12-22) (BioDeep RN: BioDeep_00000001988). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

分子结构信息

SMILES: COCCCC/C(=N\OCCN)/c1ccc(cc1)C(F)(F)F
InChI: InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3

描述信息

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065609 - Cytochrome P-450 CYP1A2 Inhibitors
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants > N06AB - Selective serotonin reuptake inhibitors
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents
C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
CONFIDENCE standard compound; INTERNAL_ID 8519
D049990 - Membrane Transport Modulators
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

45 个代谢物同义名

(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine; 2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine; Pharmascience brand OF fluvoxamine maleate; Neuraxpharm brand OF fluvoxamine maleate; Stadapharm brand OF fluvoxamine maleate; Ratiopharm brand OF fluvoxamine maleate; Merck dura brand OF fluvoxamine maleate; Betapharm brand OF fluvoxamine maleate; Novopharm brand OF fluvoxamine maleate; Nu-pharm brand OF fluvoxamine maleate; Nu pharm brand OF fluvoxamine maleate; Declimed brand OF fluvoxamine maleate; Geminis brand OF fluvoxamine maleate; Solvay brand OF fluvoxamine maleate; Aliud brand OF fluvoxamine maleate; Fluvoxamine maleate, (e)-isomer; Fluvoxamine, (Z)-isomer; Fluvoxamin neuraxpharm; Fluvoxamin-neuraxpharm; Fluvoxamin-ratiopharm; Fluvoxamin ratiopharm; Geminis, fluvoxamina; Fluvoxamine maleate; Fluvoxamina geminis; Ratio fluvoxamine; Ratio-fluvoxamine; Fluvoxamin stada; Novo fluvoxamine; Novo-fluvoxamine; Fluvoxamin beta; PMS Fluvoxamine; PMS-Fluvoxamine; Nu-fluvoxamine; Fluvoxamine-CR; Nu fluvoxamine; Fluvoxamin al; Fluvoxamine; Fluvoxadura; Floxyfral; Dumirox; Faverin; Desiflu; Fevarin; Luvox; Fluvoxamine



数据库引用编号

21 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 10 ABCB1, AXIN2, BDNF, CA1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOS3, POMC
Peripheral membrane protein 1 CYP1B1
Endosome membrane 1 SLC6A4
Endoplasmic reticulum membrane 7 CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, SIGMAR1
Nucleus 2 AXIN2, NOS3
cytosol 4 AXIN2, CA1, NOS3, SIGMAR1
dendrite 5 BDNF, HTR1A, HTR1B, HTR2A, HTR2C
centrosome 1 AXIN2
nucleoplasm 1 NOS3
Cell membrane 8 ABCB1, HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, SIGMAR1, SLC6A4
Cleavage furrow 1 HTR3A
Cell projection, axon 1 HTR2A
Multi-pass membrane protein 7 ABCB1, HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, SLC6A4
Synapse 4 HTR1A, HTR2C, HTR3A, SLC6A4
cell surface 1 ABCB1
dendritic shaft 1 HTR2A
glutamatergic synapse 2 HTR2A, SIGMAR1
Golgi apparatus 1 NOS3
Golgi membrane 1 NOS3
growth cone 1 SIGMAR1
neuronal cell body 1 HTR2A
postsynapse 1 HTR3A
presynaptic membrane 3 HTR1B, HTR2A, SLC6A4
synaptic vesicle 1 BDNF
Presynapse 2 HTR2A, SLC6A4
plasma membrane 11 ABCB1, AXIN2, CYP2C19, CYP2C9, HTR1A, HTR1B, HTR2A, HTR2C, HTR3A, NOS3, SLC6A4
Membrane 8 ABCB1, BDNF, CYP1B1, CYP2D6, CYP3A4, HTR3A, SIGMAR1, SLC6A4
apical plasma membrane 1 ABCB1
axon 2 BDNF, HTR2A
caveola 2 HTR2A, NOS3
extracellular exosome 2 ABCB1, CA1
endoplasmic reticulum 3 CYP2D6, HTR1B, SIGMAR1
extracellular space 3 BDNF, IL6, POMC
perinuclear region of cytoplasm 2 BDNF, NOS3
mitochondrion 2 CYP1B1, CYP2D6
intracellular membrane-bounded organelle 6 CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4
Microsome membrane 5 CYP1A2, CYP1B1, CYP2C9, CYP2D6, CYP3A4
postsynaptic density 1 SIGMAR1
Secreted 3 BDNF, IL6, POMC
extracellular region 3 BDNF, IL6, POMC
Single-pass membrane protein 2 CYP2D6, SIGMAR1
anchoring junction 1 SIGMAR1
beta-catenin destruction complex 1 AXIN2
cytoplasmic vesicle 2 HTR2A, SIGMAR1
Cytoplasm, P-body 1 NOS3
P-body 1 NOS3
postsynaptic membrane 3 HTR2A, HTR3A, SLC6A4
Apical cell membrane 1 ABCB1
Membrane raft 1 SLC6A4
Cell junction, focal adhesion 1 SLC6A4
focal adhesion 1 SLC6A4
secretory granule 1 POMC
Nucleus inner membrane 1 SIGMAR1
Nucleus outer membrane 1 SIGMAR1
nuclear inner membrane 1 SIGMAR1
nuclear outer membrane 1 SIGMAR1
Postsynaptic cell membrane 1 HTR3A
Cell projection, neuron projection 1 SLC6A4
neuron projection 2 HTR3A, SLC6A4
cytoskeleton 1 NOS3
serotonin-activated cation-selective channel complex 1 HTR3A
transmembrane transporter complex 1 HTR3A
nuclear envelope 1 SIGMAR1
Nucleus envelope 1 SIGMAR1
Endomembrane system 1 SLC6A4
Lipid droplet 1 SIGMAR1
Membrane, caveola 1 HTR2A
cell body fiber 1 HTR2A
Cell projection, dendrite 2 HTR1A, HTR2A
Cytoplasm, Stress granule 1 NOS3
cytoplasmic stress granule 1 NOS3
secretory granule lumen 1 POMC
endoplasmic reticulum lumen 2 BDNF, IL6
endocytic vesicle membrane 1 NOS3
postsynaptic density membrane 1 SIGMAR1
neurofilament 1 HTR2A
calyx of Held 1 HTR1B
external side of apical plasma membrane 1 ABCB1
interleukin-6 receptor complex 1 IL6
[Neurotrophic factor BDNF precursor form]: Secreted 1 BDNF
G protein-coupled serotonin receptor complex 3 HTR1B, HTR2A, HTR2C
serotonergic synapse 2 HTR1B, SLC6A4


文献列表

  • Furong Zhang, Wenting Gong, Zhou Cui, Jing Li, Yuanyuan Lu. Rhabdomyolysis in a male adolescent associated with monotherapy of fluvoxamine. European journal of hospital pharmacy : science and practice. 2022 Dec; ?(?):. doi: 10.1136/ejhpharm-2022-003533. [PMID: 36460460]
  • Wen Wen, Chen Chen, Jiake Tang, Chunyi Wang, Mengyun Zhou, Yongran Cheng, Xiang Zhou, Qi Wu, Xingwei Zhang, Zhanhui Feng, Mingwei Wang, Qin Mao. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis. Annals of medicine. 2022 12; 54(1):516-523. doi: 10.1080/07853890.2022.2034936. [PMID: 35118917]
  • Wei Zheng, He-Li Sun, Hong Cai, Qinge Zhang, Chee H Ng, Yu-Tao Xiang. Antidepressants for COVID-19: A systematic review. Journal of affective disorders. 2022 06; 307(?):108-114. doi: 10.1016/j.jad.2022.03.059. [PMID: 35339571]
  • Takuya Nagashima, Takashi Hayakawa, Hayato Akimoto, Kimino Minagawa, Yasuo Takahashi, Satoshi Asai. Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies. Clinical pharmacology and therapeutics. 2022 06; 111(6):1258-1267. doi: 10.1002/cpt.2573. [PMID: 35258103]
  • Vladimir Trkulja. Fluvoxamine for COVID-19 ICU patients?. British journal of clinical pharmacology. 2022 05; 88(5):2454-2455. doi: 10.1111/bcp.15166. [PMID: 35132670]
  • Sapan Bhuta, Waleed Khokher, Nithin Kesireddy, Saffa Iftikhar, Azizullah Beran, Mohammed Mhanna, Neha J Patel, Mitra Patel, Cameron Burmeister, Ragheb Assaly. Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis. American journal of therapeutics. 2022 May; 29(3):e298-e304. doi: 10.1097/mjt.0000000000001496. [PMID: 35383578]
  • Peter Manu. Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure. American journal of therapeutics. 2022 May; 29(3):e342-e343. doi: 10.1097/mjt.0000000000001502. [PMID: 35383592]
  • Udo Bonnet, Georg Juckel. COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review. Journal of clinical psychopharmacology. 2022 May; 42(3):284-292. doi: 10.1097/jcp.0000000000001543. [PMID: 35420565]
  • Xiaoxing Wang, Martin E Dowty, Ann Wouters, Svitlana Tatulych, Carol A Connell, Vu H Le, Sakambari Tripathy, Melissa T O'Gorman, Jennifer A Winton, Natalie Yin, Hernan Valdez, Bimal K Malhotra. Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals. European journal of drug metabolism and pharmacokinetics. 2022 May; 47(3):419-429. doi: 10.1007/s13318-021-00745-6. [PMID: 35226304]
  • Martina Calusic, Robert Marcec, Lea Luksa, Ivan Jurkovic, Natasa Kovac, Slobodan Mihaljevic, Robert Likic. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. British journal of clinical pharmacology. 2022 05; 88(5):2065-2073. doi: 10.1111/bcp.15126. [PMID: 34719789]
  • Ahmed Hassab Errasoul, Mohammed A Alarabi. Factors predicting serum clozapine levels in Middle Eastern patients: an observational study. BMC psychiatry. 2022 04; 22(1):269. doi: 10.1186/s12888-022-03910-6. [PMID: 35428222]
  • Janna K Duong, Romina A Nand, Aarti Patel, Oscar Della Pasqua, Annette S Gross. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity. Pharmacology research & perspectives. 2022 04; 10(2):e00946. doi: 10.1002/prp2.946. [PMID: 35307978]
  • Todd C Lee, Simone Vigod, Émilie Bortolussi-Courval, Ryan Hanula, David R Boulware, Eric J Lenze, Angela M Reiersen, Emily G McDonald. Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis. JAMA network open. 2022 04; 5(4):e226269. doi: 10.1001/jamanetworkopen.2022.6269. [PMID: 35385087]
  • Yazhou Sun, Weiguo Wan, Xin Zhao, Xueyu Han, Tianxin Ye, Xiaoli Chen, Qian Ran, Xiukun Wang, Xin Liu, Chuan Qu, Shaobo Shi, Cui Zhang, Bo Yang. Chronic Sigma 1 receptor activation alleviates right ventricular dysfunction secondary to pulmonary arterial hypertension. Bioengineered. 2022 04; 13(4):10843-10856. doi: 10.1080/21655979.2022.2065953. [PMID: 35473584]
  • Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto. Mechanisms of action of fluvoxamine for COVID-19: a historical review. Molecular psychiatry. 2022 04; 27(4):1898-1907. doi: 10.1038/s41380-021-01432-3. [PMID: 34997196]
  • Mohamed Mahdi, Levente Hermán, János M Réthelyi, Bálint László Bálint. Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19. International journal of molecular sciences. 2022 Mar; 23(7):. doi: 10.3390/ijms23073812. [PMID: 35409171]
  • Peter E Wu, Emily Austin, Derek Leong. Title Not Available. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2022 03; 194(11):E437-E438. doi: 10.1503/cmaj.220011-f. [PMID: 35314448]
  • Catia Marzolini, Fiona Marra, Alison Boyle, Saye Khoo, David J Back. Fluvoxamine for the treatment of COVID-19. The Lancet. Global health. 2022 03; 10(3):e331. doi: 10.1016/s2214-109x(21)00592-1. [PMID: 35180411]
  • Michael G Dodds, Eileen B Doyle, Angela M Reiersen, Fran Brown, Craig R Rayner. Fluvoxamine for the treatment of COVID-19. The Lancet. Global health. 2022 03; 10(3):e332. doi: 10.1016/s2214-109x(22)00006-7. [PMID: 35180412]
  • Gilmar Reis, Edward Mills. Fluvoxamine for the treatment of COVID-19 - Author's reply. The Lancet. Global health. 2022 03; 10(3):e333. doi: 10.1016/s2214-109x(21)00588-x. [PMID: 35180413]
  • Hyun Kim, Shannon Manzi, Joseph Gonzelez-Heydrich, Jonathan Picker. Fluvoxamine for the treatment of COVID-19. The Lancet. Global health. 2022 03; 10(3):e330. doi: 10.1016/s2214-109x(22)00003-1. [PMID: 35180410]
  • David R Boulware, Mahsa Abassi. Fluvoxamine for the treatment of COVID-19. The Lancet. Global health. 2022 03; 10(3):e329. doi: 10.1016/s2214-109x(21)00590-8. [PMID: 35180409]
  • Peter E Wu, Emily Austin, Derek Leong. Fluvoxamine for symptomatic outpatients with COVID-19. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2022 02; 194(7):E258. doi: 10.1503/cmaj.220011. [PMID: 35045990]
  • Eric J Lenze, Angela M Reiersen, Shelley N Facente. Authors' Reply to Mazza et al.: 'Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence'. Drugs. 2022 02; 82(3):353-354. doi: 10.1007/s40265-022-01681-8. [PMID: 35150436]
  • Mario Gennaro Mazza, Benedetta Vai, Livia De Picker, Francesco Benedetti, Raffaella Zanardi. Comment on: 'Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence'. Drugs. 2022 02; 82(3):349-351. doi: 10.1007/s40265-022-01682-7. [PMID: 35150437]
  • Yaeko Hashimoto, Takuji Suzuki, Kenji Hashimoto. Old drug fluvoxamine, new hope for COVID-19. European archives of psychiatry and clinical neuroscience. 2022 Feb; 272(1):161-163. doi: 10.1007/s00406-021-01326-z. [PMID: 34476589]
  • Konrad Rejdak, Paweł Grieb. Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention. Current neuropharmacology. 2022; 20(4):777-781. doi: 10.2174/1570159x19666210729123734. [PMID: 34325642]
  • Otavio Berwanger. Fluvoxamine for outpatients with COVID-19: where do we stand?. The Lancet. Global health. 2022 01; 10(1):e2-e3. doi: 10.1016/s2214-109x(21)00501-5. [PMID: 34717819]
  • Philip L Hooper. Heme oxygenase agonists-fluvoxamine, melatonin-are efficacious therapy for Covid-19. Cell stress & chaperones. 2022 01; 27(1):3-4. doi: 10.1007/s12192-021-01246-w. [PMID: 34846631]
  • Konstantinos I Papadopoulos, Warachaya Sutheesophon, Tar-Choon Aw. Anti-SARS-CoV-2 Action of Fluvoxamine may be Mediated by Endothelial Nitric Oxide Synthase. Pharmacopsychiatry. 2022 01; 55(1):57. doi: 10.1055/a-1641-0357. [PMID: 34555857]
  • Gilmar Reis, Eduardo Augusto Dos Santos Moreira-Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Aline Cruz Milagres, Thiago Santiago Ferreira, Castilho Vitor Quirino Dos Santos, Vitoria Helena de Souza Campos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes de Almeida, Eduardo Diniz Callegari, Adhemar Dias de Figueiredo Neto, Leonardo Cançado Monteiro Savassi, Maria Izabel Campos Simplicio, Luciene Barra Ribeiro, Rosemary Oliveira, Ofir Harari, Jamie I Forrest, Hinda Ruton, Sheila Sprague, Paula McKay, Alla V Glushchenko, Craig R Rayner, Eric J Lenze, Angela M Reiersen, Gordon H Guyatt, Edward J Mills. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet. Global health. 2022 01; 10(1):e42-e51. doi: 10.1016/s2214-109x(21)00448-4. [PMID: 34717820]
  • Abir T El-Alfy, Kristin Busse. Fluvoxamine and COVID-19. WMJ : official publication of the State Medical Society of Wisconsin. 2022; 121(?):P2. doi: NULL. [PMID: 35671339]
  • Shelley N Facente, Angela M Reiersen, Eric J Lenze, David R Boulware, Jeffrey D Klausner. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. Drugs. 2021 Dec; 81(18):2081-2089. doi: 10.1007/s40265-021-01636-5. [PMID: 34851510]
  • Allan H Young. Repurposing psychopharmacology: A two-way street?. Journal of psychopharmacology (Oxford, England). 2021 12; 35(12):1439-1440. doi: 10.1177/02698811211064648. [PMID: 34872403]
  • Tomiko Oskotsky, Ivana Maric, Alice Tang, Boris Oskotsky, Ronald J Wong, Nima Aghaeepour, Marina Sirota, David K Stevenson. Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants. JAMA network open. 2021 11; 4(11):e2133090. doi: 10.1001/jamanetworkopen.2021.33090. [PMID: 34779847]
  • Nicolas Hoertel. Do the Selective Serotonin Reuptake Inhibitor Antidepressants Fluoxetine and Fluvoxamine Reduce Mortality Among Patients With COVID-19?. JAMA network open. 2021 11; 4(11):e2136510. doi: 10.1001/jamanetworkopen.2021.36510. [PMID: 34779851]
  • Tomoyuki Hioki, Haruhiko Tokuda, Kumiko Tanabe, Woo Kim, Junko Tachi, Shinobu Yamaguchi, Rie Matsushima-Nishiwaki, Osamu Kozawa, Hiroki Iida. Amplification by tramadol of PGD2-induced osteoprotegerin synthesis in osteoblasts: Involvement of μ-opioid receptor and 5-HT transporter. Prostaglandins, leukotrienes, and essential fatty acids. 2021 09; 172(?):102323. doi: 10.1016/j.plefa.2021.102323. [PMID: 34392133]
  • Jakub Staroń, Wojciech Pietruś, Ryszard Bugno, Rafał Kurczab, Grzegorz Satała, Dawid Warszycki, Tomasz Lenda, Anna Wantuch, Adam S Hogendorf, Agata Hogendorf, Beata Duszyńska, Andrzej J Bojarski. Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine. European journal of medicinal chemistry. 2021 Aug; 220(?):113533. doi: 10.1016/j.ejmech.2021.113533. [PMID: 34049262]
  • Thang L Pham, Azucena H Kakazu, Jiucheng He, Robert Nshimiyimana, Nicos A Petasis, Bokkyoo Jun, Nicolas G Bazan, Haydee E P Bazan. Elucidating the structure and functions of Resolvin D6 isomers on nerve regeneration with a distinctive trigeminal transcriptome. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2021 08; 35(8):e21775. doi: 10.1096/fj.202100686r. [PMID: 34245621]
  • Michael Zastrozhin, Valentin Skryabin, Valeriy Smirnov, Anastasiya Zastrozhina, Elena Grishina, Kristina Ryzhikova, Irina Bure, Pavel Golovinskii, Sergey Koporov, Evgeniy Bryun, Dmitry Sychev. Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. American journal of therapeutics. 2021 Jun; 29(1):e26-e33. doi: 10.1097/mjt.0000000000001388. [PMID: 34117140]
  • Mary M McDermott, Anne B Newman. Remote Research and Clinical Trial Integrity During and After the Coronavirus Pandemic. JAMA. 2021 05; 325(19):1935-1936. doi: 10.1001/jama.2021.4609. [PMID: 33885728]
  • M M Salim, Mona E El Sharkasy, F Belal, M Walash. Multi-spectroscopic and molecular docking studies for binding interaction between fluvoxamine and human serum albumin. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2021 May; 252(?):119495. doi: 10.1016/j.saa.2021.119495. [PMID: 33524820]
  • NULL. Fluvoxamine for COVID-19?. The Medical letter on drugs and therapeutics. 2021 05; 63(1623):69-70. doi: NULL. [PMID: 33976099]
  • Udo Bonnet, Georg Juckel, Norbert Scherbaum, Martin Schaefer, Bernhard Kis, Simon Cohen, Jens Kuhn. Are Persons Treated with Antidepressants and/or Antipsychotics Possibly Better Protected against Severe COVID 19?. Pharmacopsychiatry. 2021 05; 54(3):142-143. doi: 10.1055/a-1408-8298. [PMID: 33733436]
  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Claudia Vignali, Matteo Moretti, Jessica Quaiotti, Francesca Freni, Luca Tajana, Antonio Marco Maria Osculati, Luca Morini. Distribution of Fluvoxamine and Identification of the Main Metabolite in a Fatal Intoxication. Journal of analytical toxicology. 2021 Apr; 45(4):e1-e5. doi: 10.1093/jat/bkaa084. [PMID: 32672818]
  • Julie Leising, Alasdair M Barr, Ric M Procyshyn, Nicholas J Ainsworth, Randall F White, William Honer, Fidel Vila-Rodriguez. High-Dose Fluvoxamine Augmentation to Clozapine in Treatment-Resistant Psychosis. Journal of clinical psychopharmacology. 2021 Mar; 41(2):186-190. doi: 10.1097/jcp.0000000000001342. [PMID: 33587389]
  • Steven Lehrer, Peter H Rheinstein. Homozygosity for rs17775810 Minor Allele Associated With Reduced Mortality of COVID-19 in the UK Biobank Cohort. In vivo (Athens, Greece). 2021 Mar; 35(2):965-968. doi: 10.21873/invivo.12338. [PMID: 33622890]
  • Markus Blaess, Lars Kaiser, Oliver Sommerfeld, René Csuk, Hans-Peter Deigner. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19. International journal of molecular sciences. 2021 Feb; 22(4):. doi: 10.3390/ijms22041797. [PMID: 33670304]
  • George M Anderson. Fluvoxamine, melatonin and COVID-19. Psychopharmacology. 2021 02; 238(2):611. doi: 10.1007/s00213-020-05753-z. [PMID: 33392622]
  • M S Zastrozhin, VYu Skryabin, VYu Smirnov, A K Zastrozhina, E V Kaverina, D A Klepikov, E A Grishina, K A Ryzhikova, I V Bure, E A Bryun, D A Sychev. Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin. 2021 01; 51(1):69-80. doi: . [PMID: 33897064]
  • Eric Lenze. COVID-19 Clinical Trials: A Voice From the Front Lines. Narrative inquiry in bioethics. 2021; 11(1):16-19. doi: 10.1353/nib.2021.0005. [PMID: 34334458]
  • O V Kotova, V E Medvedev, E S Akarachkova, A A Belyaev. [COVID-19 and stress-related disorders]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2021; 121(5. Vyp. 2):122-128. doi: 10.17116/jnevro2021121052122. [PMID: 34405668]
  • Christopher W Seymour, Howard Bauchner, Robert M Golub. COVID-19 Infection-Preventing Clinical Deterioration. JAMA. 2020 12; 324(22):2300. doi: 10.1001/jama.2020.21720. [PMID: 33180115]
  • Eric J Lenze, Caline Mattar, Charles F Zorumski, Angela Stevens, Julie Schweiger, Ginger E Nicol, J Philip Miller, Lei Yang, Michael Yingling, Michael S Avidan, Angela M Reiersen. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020 12; 324(22):2292-2300. doi: 10.1001/jama.2020.22760. [PMID: 33180097]
  • Sunita Bishnoi, Ashutosh Sharma, Rahul Singhal, Rajendra N Goyal. Edge plane pyrolytic graphite as a sensing surface for the determination of fluvoxamine in urine samples of obsessive-compulsive disorder patients. Biosensors & bioelectronics. 2020 Nov; 168(?):112489. doi: 10.1016/j.bios.2020.112489. [PMID: 32882472]
  • Wei Zheng, Ying-Qiang Xiang, Dong-Bin Cai, Xin-Hu Yang, Ling Zhang, Wei Zheng, Xiao-Bing Lu, Yan-Ming Tong, Xiong Huang, Gabor S Ungvari, Kang Sim, Yu-Ping Ning, Yu-Tao Xiang. Adjunctive Fluvoxamine for Schizophrenia: A Meta-analysis of Randomized Double-Blind, Placebo-Controlled Trials. Journal of clinical psychopharmacology. 2020 Jul; 40(4):386-390. doi: 10.1097/jcp.0000000000001245. [PMID: 32618683]
  • Emily J Cicali, D Max Smith, Benjamin Q Duong, Lukas G Kovar, Larisa H Cavallari, Julie A Johnson. A Scoping Review of the Evidence Behind Cytochrome P450 2D6 Isoenzyme Inhibitor Classifications. Clinical pharmacology and therapeutics. 2020 07; 108(1):116-125. doi: 10.1002/cpt.1768. [PMID: 31910286]
  • Mojtaba Soleimani, Ameneh Porgham Daryasari, Parisa Joshani. Molecularly Imprinted Polymer Nanoparticles for Selective Solid Phase Extraction of Fluvoxamine in Human Urine and Plasma. Journal of chromatographic science. 2020 Apr; 58(3):274-279. doi: 10.1093/chromsci/bmz092. [PMID: 31807753]
  • Ernest Dallé, William M U Daniels, Musa V Mabandla. Long-Term Treatment with Fluvoxamine Decreases Nonmotor Symptoms and Dopamine Depletion in a Postnatal Stress Rat Model of Parkinson's Disease. Oxidative medicine and cellular longevity. 2020; 2020(?):1941480. doi: 10.1155/2020/1941480. [PMID: 32273939]
  • Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
  • Yoichi Tanikawa, Mihoko Hagiwara-Nagasawa, Ryuichi Kambayashi, Ai Goto, Koki Chiba, Kumiko Kitta, Kiyotaka Hoshiai, Hiroko Izumi-Nakaseko, Atsuhiko T Naito, Atsushi Sugiyama. Characterization of microminipig as a laboratory animal for safety pharmacology study by analyzing fluvoxamine-induced cardiovascular and dermatological adverse reactions. Cardiovascular toxicology. 2019 10; 19(5):412-421. doi: 10.1007/s12012-019-09509-w. [PMID: 30734885]
  • Marc Augustin, Georgios Schoretsanitis, Philippe Pfeifer, Gerhard Gründer, Claus Liebe, Michael Paulzen. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophrenia research. 2019 08; 210(?):143-148. doi: 10.1016/j.schres.2019.05.033. [PMID: 31182321]
  • Abdullah Al Maruf, Alexandra Greenslade, Paul D Arnold, Chad Bousman. Antidepressant pharmacogenetics in children and young adults: A systematic review. Journal of affective disorders. 2019 07; 254(?):98-108. doi: 10.1016/j.jad.2019.05.025. [PMID: 31112844]
  • Hannah Britz, Nina Hanke, Anke-Katrin Volz, Olav Spigset, Matthias Schwab, Thomas Eissing, Thomas Wendl, Sebastian Frechen, Thorsten Lehr. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. CPT: pharmacometrics & systems pharmacology. 2019 05; 8(5):296-307. doi: 10.1002/psp4.12397. [PMID: 30762305]
  • Magdalene M Assimon, M Alan Brookhart, Jennifer E Flythe. Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis. Journal of the American Society of Nephrology : JASN. 2019 04; 30(4):611-623. doi: 10.1681/asn.2018101032. [PMID: 30885935]
  • Ako Sasao, Michiyo Takaki, Hee-Jin Jeong, Kosei Yonemitsu, Yuki Ohtsu, Hiroshi Tsutsumi, Shota Furukawa, Hiroshi Morioka, Hiroshi Ueda, Yoko Nishitani. Development of a fluvoxamine detection system using a Quenchbody, a novel fluorescent biosensor. Drug testing and analysis. 2019 Apr; 11(4):601-609. doi: 10.1002/dta.2520. [PMID: 30328685]
  • Yan Li, Liangang Liu, Xiaomin Wang, Chengyue Zhang, Josephine Reyes, Matthew Hoffmann, Maria Palmisano, Simon Zhou. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects. Journal of clinical pharmacology. 2018 10; 58(10):1295-1304. doi: 10.1002/jcph.1145. [PMID: 29762875]
  • Rintaro Ohno, Hiroko Miyagishi, Minoru Tsuji, Atsumi Saito, Kazuya Miyagawa, Kazuhiro Kurokawa, Hiroshi Takeda. Yokukansan, a traditional Japanese herbal medicine, enhances the anxiolytic effect of fluvoxamine and reduces cortical 5-HT2A receptor expression in mice. Journal of ethnopharmacology. 2018 Apr; 216(?):89-96. doi: 10.1016/j.jep.2018.01.032. [PMID: 29382554]
  • Mong-Liang Lu, Tzu-Ting Chen, Po-Hsiu Kuo, Ching-Chi Hsu, Chun-Hsin Chen. Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: A 12-week, randomized, double-blind, placebo-controlled study. Schizophrenia research. 2018 03; 193(?):126-133. doi: 10.1016/j.schres.2017.06.030. [PMID: 28688742]
  • Jonathan A Coleman, Eric Gouaux. Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Nature structural & molecular biology. 2018 02; 25(2):170-175. doi: 10.1038/s41594-018-0026-8. [PMID: 29379174]
  • Vincent A de Weger, Sanjay Goel, Roger von Moos, Jan H M Schellens, Nicholas Mach, Eugene Tan, Suraj Anand, Jeffrey W Scott, Ulrik Lassen. A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2018 01; 81(1):73-80. doi: 10.1007/s00280-017-3469-4. [PMID: 29101463]
  • Sayo Matsuoka, Satoko Hori, Hiroki Satoh, Takeshi Nagamatsu, Tomoyuki Fujii, Yasufumi Sawada. Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. Placenta. 2017 Oct; 58(?):74-81. doi: 10.1016/j.placenta.2017.08.010. [PMID: 28962699]
  • Dongqin Yang, Yanyan He, Funan Chen. Determination of fluvoxamine maleate in human urine and human serum using alkaline KMnO4 -rhodamine B chemiluminescence. Luminescence : the journal of biological and chemical luminescence. 2017 Sep; 32(6):1077-1083. doi: 10.1002/bio.3294. [PMID: 28371383]
  • Majid Ghareghani, Kazem Zibara, Heibatollah Sadeghi, Shima Dokoohaki, Hossein Sadeghi, Roya Aryanpour, Amir Ghanbari. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Scientific reports. 2017 07; 7(1):4923. doi: 10.1038/s41598-017-04968-z. [PMID: 28687730]
  • Ernest Dallé, Willie M U Daniels, Musa V Mabandla. Fluvoxamine maleate effects on dopamine signaling in the prefrontal cortex of stressed Parkinsonian rats: Implications for learning and memory. Brain research bulletin. 2017 06; 132(?):75-81. doi: 10.1016/j.brainresbull.2017.05.014. [PMID: 28549887]
  • Andreas Austgulen Westin, Malin Brekke, Espen Molden, Eirik Skogvoll, Olav Spigset. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. PloS one. 2017; 12(7):e0181082. doi: 10.1371/journal.pone.0181082. [PMID: 28708853]
  • Ernest Dallé, Willie M U Daniels, Musa V Mabandla. Fluvoxamine maleate normalizes striatal neuronal inflammatory cytokine activity in a Parkinsonian rat model associated with depression. Behavioural brain research. 2017 01; 316(?):189-196. doi: 10.1016/j.bbr.2016.08.005. [PMID: 27569183]
  • Adam Hosszu, Zsuzsanna Antal, Lilla Lenart, Judit Hodrea, Sandor Koszegi, Dora B Balogh, Nora F Banki, Laszlo Wagner, Adam Denes, Peter Hamar, Peter Degrell, Adam Vannay, Attila J Szabo, Andrea Fekete. σ1-Receptor Agonism Protects against Renal Ischemia-Reperfusion Injury. Journal of the American Society of Nephrology : JASN. 2017 Jan; 28(1):152-165. doi: 10.1681/asn.2015070772. [PMID: 27056295]
  • Nageshwar R Budha, Tao Ji, Luna Musib, Steve Eppler, Mark Dresser, Yuan Chen, Jin Y Jin. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical pharmacokinetics. 2016 11; 55(11):1435-1445. doi: 10.1007/s40262-016-0412-5. [PMID: 27225997]
  • Ernest Dallé, Willie M U Daniels, Musa V Mabandla. Anti-parkinsonian effects of fluvoxamine maleate in maternally separated rats. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 2016 Oct; 53(?):26-34. doi: 10.1016/j.ijdevneu.2016.06.004. [PMID: 27338206]
  • Kristine Skoglund Ask, Turgay Bardakci, Marthe Petrine Parmer, Trine Grønhaug Halvorsen, Elisabeth Leere Øiestad, Stig Pedersen-Bjergaard, Astrid Gjelstad. Parallel artificial liquid membrane extraction as an efficient tool for removal of phospholipids from human plasma. Journal of pharmaceutical and biomedical analysis. 2016 Sep; 129(?):229-236. doi: 10.1016/j.jpba.2016.07.011. [PMID: 27433988]
  • Norio Yasui-Furukori, Shoko Tsuchimine, Kazutoshi Kubo, Masamichi Ishioka, Kazuhiko Nakamura, Yoshimasa Inoue. The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients. Therapeutic drug monitoring. 2016 08; 38(4):483-6. doi: 10.1097/ftd.0000000000000303. [PMID: 27002781]
  • Heng-Yen Wang, Yajuan Qin, Huiying Li, Linda J Roman, Pavel Martásek, Thomas L Poulos, Richard B Silverman. Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. Journal of medicinal chemistry. 2016 05; 59(10):4913-25. doi: 10.1021/acs.jmedchem.6b00273. [PMID: 27050842]
  • Akihiro Mouri, Masashi Ikeda, Takenao Koseki, Nakao Iwata, Toshitaka Nabeshima. The ubiquitination of serotonin transporter in lymphoblasts derived from fluvoxamine-resistant depression patients. Neuroscience letters. 2016 Mar; 617(?):22-6. doi: 10.1016/j.neulet.2016.01.064. [PMID: 26845564]
  • Christoffer Polcwiartek, Jimmi Nielsen. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology. 2016 Mar; 233(5):741-50. doi: 10.1007/s00213-015-4161-1. [PMID: 26626327]
  • Eric L Singman, Brian Hocum, Jithin Yohannan, Virginia Pearson. Fluvoxamine-associated oscillopsia and a role for personalized medication dosing. Drug metabolism and personalized therapy. 2015 Dec; 30(4):271-5. doi: 10.1515/dmpt-2015-0006. [PMID: 26351962]
  • Monica Hermann, Ragnhild Birkeland Waade, Espen Molden. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Therapeutic drug monitoring. 2015 Aug; 37(4):546-9. doi: 10.1097/ftd.0000000000000169. [PMID: 25565671]
  • Javad Hassanzadeh, Mohammad Amjadi. Sensitive and selective determination of fluvoxamine maleate using a sensitive chemiluminescence system based on the alkaline permanganate-Rhodamine B-gold nanoparticles reaction. Luminescence : the journal of biological and chemical luminescence. 2015 Jun; 30(4):439-43. doi: 10.1002/bio.2757. [PMID: 25214010]
  • M Kato, A Serretti, S Nonen, Y Takekita, M Wakeno, J Azuma, T Kinoshita. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational psychiatry. 2015 Feb; 5(?):e513. doi: 10.1038/tp.2015.6. [PMID: 25710119]
  • Yukiko Yamazaki-Hashimoto, Yuji Nakamura, Hiroshi Ohara, Xin Cao, Ken Kitahara, Hiroko Izumi-Nakaseko, Kentaro Ando, Hiroshi Yamazaki, Takanori Ikeda, Junichi Yamazaki, Atsushi Sugiyama. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. The Journal of toxicological sciences. 2015 Feb; 40(1):33-42. doi: 10.2131/jts.40.33. [PMID: 25560394]
  • Jafar Abolhasani, Javad Hassanzadeh. Potassium permanganate-acridine yellow chemiluminescence system for the determination of fluvoxamine, isoniazid and ceftriaxone. Luminescence : the journal of biological and chemical luminescence. 2014 Dec; 29(8):1053-8. doi: 10.1002/bio.2659. [PMID: 24753178]
  • Sylvia Montañez, Jaclyn L Munn, W Anthony Owens, Rebecca E Horton, Lynette C Daws. 5-HT1B receptor modulation of the serotonin transporter in vivo: studies using KO mice. Neurochemistry international. 2014 Jul; 73(?):127-31. doi: 10.1016/j.neuint.2013.11.004. [PMID: 24246466]
  • M Gahr, K Rehbaum, B J Connemann. Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on. Pharmacopsychiatry. 2014 May; 47(3):118-20. doi: 10.1055/s-0034-1374611. [PMID: 24846087]
  • L M Kong, S Y Xu, H H Hu, H Zhou, H D Jiang, L S Yu, S Zeng. Identification of CYP2C19 inhibitors from phytochemicals using the recombinant human enzyme model. Die Pharmazie. 2014 May; 69(5):362-6. doi: ". [PMID: 24855828]
  • Shinya Uchida, Shimako Tanaka, Noriyuki Namiki. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats. Biopharmaceutics & drug disposition. 2014 May; 35(4):228-36. doi: 10.1002/bdd.1888. [PMID: 24395703]
  • Saloua Benmansour, Anthony A Privratsky, Opeyemi S Adeniji, Alan Frazer. Signaling mechanisms involved in the acute effects of estradiol on 5-HT clearance. The international journal of neuropsychopharmacology. 2014 May; 17(5):765-77. doi: 10.1017/s146114571300165x. [PMID: 24423185]
  • Hanna S Lindgren, Merve Demirbugen, Filip Bergqvist, Emma L Lane, Stephen B Dunnett. The effect of additional noradrenergic and serotonergic depletion on a lateralised choice reaction time task in rats with nigral 6-OHDA lesions. Experimental neurology. 2014 Mar; 253(?):52-62. doi: 10.1016/j.expneurol.2013.11.015. [PMID: 24333808]
  • Hirotoshi Sato, Chihiro Ito, Manabu Tashiro, Kotaro Hiraoka, Katsuhiko Shibuya, Yoshihito Funaki, Ren Iwata, Hiroo Matsuoka, Kazuhiko Yanai. Histamine H₁ receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. Psychopharmacology. 2013 Nov; 230(2):227-34. doi: 10.1007/s00213-013-3146-1. [PMID: 23728612]